ImmuneOncia Rights Offering: Final Price at 4,860 Won, Raising ₩81.8B for IMC-001 Commercialization

Final offering price set at 4,860 won, down from initial 6,260 won; total proceeds reduced to ₩81.8B (from ₩105.4B)
All proceeds allocated to IMC-001 (Danburstotug) commercialization (CMC, R&D, regulatory), execution planned 2026-2028
Major shareholder Yuhan to subscribe ₩15B; stake to drop from 65.75% to 56.24% after the rights offering
As of end-2025: capital impairment 23.4%, net loss ₩27.4B, pre-tax loss ratio 96.3%
IMC-001 Phase 2 NKTCL: ORR 79%, CR 63%, orphan drug designation (ODD) obtained
Risks include tech transfer delays (3D Medicines) and frequent capital raising